Table 1.
Chemical series | Therapeutics | Development stage |
---|---|---|
Inhibitors of MDM2-p53 interaction by targeting to MDM2 | ||
Cis-imidazoline | RO5045337 (RG7112; Nutlin-3) | Phase I: Advanced solid tumors and hematological malignancy |
Benzodiazepinedione | TDP521252 & TDP665759 | Preclinical |
Spiro-oxindoles | MI-219, MI-319 & other MI compounds |
Preclinical |
Isoquinolinone | PXN727 & PXN822 | Preclinical |
Inhibitor of MDM2-p53 interaction by targeting to p53 | ||
Thiophene | RITA (NSC 652287) |
Preclinical |
E3 Ligase Inhibitors | ||
5-Deazaflavin | HLI98 compounds | Preclinical |
Tryptamine | JNJ-26854165 | Phase I: Advanced solid tumors |